Molecular differences in colon cancer according to location: A literature review


Hell J Surg. 2023 Jul-Sep; 93(1): 34-41
doi: 10.59869/23005

Alexandros Apostolopoulos1, Athina Isaakidou2, Eleni Demetriou1, Athanasios Marinis3, Georgios Ayiomamitis4, Marios Karaiskakis1

1Department of General Surgery, German Oncology Center, Limassol, Cyprus
2Department of Medical Oncology, German Oncology Center, Limassol, Cyprus
3Third Department of Surgery, Tzaneio General Hospital, Piraeus, Greece
4First Department of Surgery, Tzaneio General Hospital, Piraeus, Greece

Correspondence:  Alexandros Apostolopoulos, German Oncology Center, Limassol, Cyprus, 1, Nikis Avenue, P.O. 4108, Agios Athanasios, Limassol, Cyprus, e-mail:


Differences in clinical presentation, epidemiology, prognosis, and molecular mechanisms between left-sided colon cancer (LCC) and right-sided colon cancer (RCC) have been widely studied in recent years. Indeed, mutations seen in LCC differ in nature and frequency compared to LCC. Furthermore, the differences in the biological environment, including histopathological, microbiological, and biochemical differences of the two regions promote different gene expressions in carcinomas. These molecular differences distinguish the nature of colorectal cancer according to the primary site of formation. In this narrative review, all such differences have been explored in detail with the aim of providing further insights into the topic, since in the era of individualised treatment, sidedness is a major factor in the treatment of colorectal cancer.

Key Words: Colorectal cancer, primary tumour location, sidedness, molecular differences

Submission: 01.05.23, Acceptance: 13.06.2023


Colon cancer, otherwise known as colorectal cancer (CRC), is the third most common cancer (after lung and breast cancers) and the second most common cause of death associated with cancer worldwide, regardless of gender [1]. The number of deaths caused by CRC has been decreasing in the last decade, possibly due to early diagnosis with screening programs and novel therapeutics [2,3]. Nevertheless, the disease continues to be of paramount significance in the field of oncology. Colorectal cancer can be caused by both genetic disorders (as in hereditary colon cancer), or environmental factors (as in sporadic colon cancer) [4]. Sporadic colon cancer, consisting of approximately 95% of all CRC cases, is associated both with genetic predisposition or gene mutations, as well as other risk factors, including some related to lifestyle such as obesity, lack of exercise, diet, smoking and alcohol consumption [5,6]. It is therefore necessary to study the molecular mechanisms of CRC carcinogenesis, as it can lead to the discovery of novel screening and therapeutic methods, which can assist the diagnosis and prognosis clinically.

Traditionally, the large bowel has been categorised into three main groups, the proximal or right colon, the distal or left colon and the rectum. The border of the right and left colon is the point between the proximal two thirds and the distal third of the transverse colon [7]. This reflects the differences in embryologic development [8]. From the midgut arise the superior mesenteric artery and vein, which vascularize the cecum, the ascending colon and the proximal two thirds of the transverse colon, while the distal transverse, the descending colon and the sigmoid colon are irrigated by the inferior mesenteric artery and vein, which derive from the hindgut [7]. Colon cancers are considered right sided or proximal if they are located before the splenic flexure. Left-sided colorectal cancers or distal carcinomas are cancers found distal to the splenic flexure. Tumours found in the splenic flexure are considered left-sided colon cancers [9]. Due to their embryologic origin, cancers of the right colon resemble gastric carcinomas and small bowel tumours [10,11]. It is of interest that neoplasms of the appendix and distal small bowel, although of shared embryologic descent and vascularisation with the right colon, are not included in the right sided colon cancer group [10]. They have differences in carcinogenesis and therefore are not in this group. Additionally, rectal carcinomas share similar molecular pathways with the distal large bowel and are considered left-sided cancers [11,12].


Multiple mutations of oncogenes and tumour suppressor genes occur in the oncogenesis process of colon cancer. Two main pathogenic pathways are involved in this sequence [13]. The first pathway involves the APC and β-catenin genes and features chromosomal instability. Normally, the APC tumour suppressor gene promotes β-catenin degradation [14]. The APC tumour suppressor gene is lost in this pathway, an event which promotes the development of an adenoma and occurs early in this process. The accumulation of β-catenin forces it to translocate to the nucleus. This activates the transcription of MYC and cyclin D1 genes. Mutations of the K-RAS gene begin to occur and subsequently mutations of the 18q21 and TP53 genes occur [13,15].  The second pathway consists of damage to DNA mismatch repair genes and accounts for approximately 10-15% of all cases of sporadic cancer [16,17]. The most common of these DNA mismatch repair genes to have genetic lesions is MLH1, resulting in a hypermutable state where repetitive DNA sequences, called microsatellites, become unstable during DNA replication [18]. This phenomenon, called microsatellite instability (MSI), characterises defective DNA mismatch repair, which results in the accumulation of mutations of growth-regulating genes and further development of colorectal cancer. In addition to these two main pathways, the CpG island methylator phenotype (CIMP) pathway is also involved in the CRC carcinogenesis [19].

Colorectal cancer is a heterogeneous disease which develops through various genetic and epigenetic mutations, with three distinct molecular pathways. These are chromosomal instability (CIN), microsatellite instability (MSI) and epigenetic methylation (Serated/CIMP) [19,20]. Chromosomal instability refers to many structural and numerical changes in chromosomes. This means whole chromosomes or parts of them are duplicated, inserted, or deleted, leading to aneuploidy [21].

Microsatellites, also known as Short Tandem Repeats (STR), are repeated sequences of DNA, with 1-4 bases per unit that are repeated and scattered throughout the genome, in areas that are coding or non-coding regions and account for about 3% of the entire genome [22]. Due to their repeated structure, they are susceptible to multiple errors and mutations during DNA replication. The system that corrects these errors is called DNA mismatch repair (MMR) [23]. Microsatellite instability is defined as the result of impaired MMR, which is phenotypically evident when there is a change in length of microsatellites. MSI occurs in genetically inherited mutations of MMR genes, such as Lynch syndrome, or in an epigenetic inactivation of these genes during methylation of MLH1 [18]. Carcinomas with high microsatellite instability are called MSI deficient, or MSI-d, whereas carcinomas with stable microsatellites are called MSI-proficient or MSI-p. Microsatellites that are unstable are highly immunogenic. This has an excellent effect with treatments of unstable tumours that activates the immune system [24,25].


Gene expression and tumor position

Gene expression in the normal colon varies between right and left side. For example, cytochrome p450 genes are expressed more in the right colon compared to the left colon in normal subjects. This may be due to differences in exposure of materials consumed in the colon [11]. Furthermore, methylation of genes is different on each side of the large bowel. The mismatch repair gene hMLH1 and the O-6-methylguanine-DNA methyltransferase MGMT is found predominantly in the normal right colon of older females [11,26]. This may reflect epigenetic abnormalities that may lead to dysplasia and further development of adenocarcinomas of the right colon.

The CIMP phenotype consists of hypermethylation of CpG islands. These are clusters of cytosine-guanine complexes. CIMP is an epigenetic control aberration that is important for inactivation of onco-suppressor genes in cancer cells. Under normal circumstances, these areas are not methylated [20]. When hypermethylation occurs and onco-suppressor genes are inactivated, carcinogenesis may develop. According to the proportion of CpG islands methylated, tumours are divided into CIMP-high, CIMP low and CIMP-normal groups. CIMP-high tumours are often associated with microsatellite instability due to hypermethylation of MMR genes, and with BRAF mutations but are usually wild type for p53 mutations [27].

In 2015, in order to resolve inconsistencies in classifications of CRC based on gene expression, an international consensus decision was made on the molecular subtypes of colorectal cancer [28]. Four consensuses of molecular subtypes with distinguishing features were defined (CMSs). The CMS1 (microsatellite instability immune) subtype, consisting of 14% of CRCs, has the best prognosis but worse survival after recurrence. They are hypermutated and microsatellite unstable and are immunogenic; CMS1 samples were hypermutated and had low prevalence of somatic copy number alterations, and they had overexpression of proteins involved in DNA damage repair. As expected, the analysis of methylation profiles in TCGA showed that CMS1 tumours display a widespread hypermethylation status; The CMS2 subtype or canonical subtype is epithelial and occur in 37% of CRCs and have the highest overall survival. They detected more frequent copy number gains in oncogenes and copy number losses in tumor suppressor genes in CMS2 than in the other subtypes; the CMS3 subtype or the metabolic subtype occurs in 13% of cases and are also epithelial [29]. They also have an evident metabolic cancer phenotype; the CMS4 subtype, or the mesenchymal subtype occurs in 23 % of cases is prominent transforming growth factor-β activation, stromal invasion, and angiogenesis [30].

Molecular differences in colon cancer according to location can be seen using the molecular subtypes. In right colon cancer, CMS1 and CMS3 are more common, while CMS2 and CMS4 are more common in left colon cancer [11]. All subtypes are found on both sides, but the proportion is different according to location. CMS has been proved to be a significant clinical prognostic factor in overall survival (OR) and progression-free survival (PFS). In CMS1 groups, patients treated with bevacizumab had significantly better overall OS than those treated with cetuximab. In the CMS2 group, patients treated with cetuximab had significantly longer OS than patients treated with bevacizumab [31,32].

Carcinomas of the right colon are usually CIMP-high; they are also MSI high, hypermutated, and have a high affinity for BRAF mutations, especially the V600E mutation. Several other gene mutations such as KRAS, PIK3CA and RNF43 are found more frequently in RCC. Some gene mutations are exclusive to the right side. These genes are CDH1, MRE11, SMAD2 and NOTCH1 [11,33,34]. BRAF mutations and CIMP-high status have poor prognosis, giving right-sided colon cancer generally a worse prognosis than LCC [35,36]. Adversely, left sided colon cancers are microsatellite stable, they present chromosomal instability and APC and p53 mutations and genes that have Tyrosine Kinase Receptors are augmented, causing the upregulation of HER2 and EGFR genes [25,36,37].

Genes whose mutations are associated with cancer predisposing syndromes like Lynch syndrome, juvenile polyposis syndrome, PTEN hamartoma tumour syndrome, neurofibromatosis type 2 and hereditary breast ovarian cancer syndrome have slightly higher prevalence in RCC, which are namely the MSH6, MLH1, MSH2, POLE, PTEN, BMPR1A, BRCA1, BAP1, BRIP1, NF2, and MEN1 genes [11,26,37-39].

Differences in immunohistochemistry amongst right and left side cancers have also been identified. The expression of programmed cell death (PD-1) and PD-1 ligand-1 (PDL-1) is expressed approximately two times more in RCC rather than LCC [11,40,41]. The molecular differences mentioned are presented in Figure 1, Table 1.

Figure 1. Main significant gene mutations in colon cancer per location.


The microenvironment of the large bowel lumen plays an important role in the development of colorectal cancer. Environmental factors such as distinct microbiota, bile acid levels and chronic inflammation may contribute to carcinogenesis of the intestinal epithelial cells [44]. The microenvironment in the right side of the colon differs from the left side, which also affects the expression of genes between the regions.

Differences in the microbiota

The large bowel hosts a large number of different bacteria, including E.coli, and F.nucleatum and the percentage of these bacterial species is quite similar in the left side and the right side of the colon, accounting the microbe population of the colon as uniform [45]. Nevertheless, this balance changes when colon cancer develops and differences in bacterial flora exist between patients with left and right sided colon cancer [46] .

Carcinogenesis related to bacterial exposure occurs via two different pathways. The first pathway has to do with chronic inflammation related to colitis and the bacteria responsible for this situation are usually E. coli, B.fragilis, B.dorei, B.vulgatus and B.massiliensis [47]. The second pathway consists of the creation of a microenvironment by different bacterial strains, which promotes immunological response and inflammation not related to colitis and bacterial strains involved in this second pathway are usually F.nucleatum, Pophyromonas, Parvimonas and Leptotrichiae [40].

E.coli are very common microorganisms and are part of the normal gut and the majority of group B2 E.coli can harbour genomic pks islands, which are responsible for the production of polyketide synthase [48]. In turn, polyketide synthase can cause double strand breaks in DNA which in turn causes an increase in γH2AX histones. These histones create polyploidy due to incomplete DNA repair, which can also create anaphasic bridges leading essentially to multiple mutations [49]. It is worth mentioning that the incidence of group B2 E.coli in biopsies of patients with right-sided colon cancer has been found to be higher in comparison to patients with left sided colon cancer [50].

F.nucleatum is the most studied of all oncogenic bacteria and has been found to have the most malignant potential and is found in a vast number of colorectal cancer patients, bound to mucin-producing cells of the intestinal lumen [51]. It binds to intestinal mucosa in two ways, with FadA and Fap 2 receptors. It promotes an inflammatory microenvironment without colitis (NF-κB, IL-6,IL-8, IL-10, IL-18, and TNF) and via other pathways it creates an immune-deficient environment (by recruiting myeloid-derived suppressor cells or MDSC’s  with short chain fatty acids and polypeptides) by  reducing CD3+ T-lymphocytes and promoting the beta-catenin pathway [52,53]. The result is cellular dysplasia and carcinogenesis. Interestingly, levels of F.nucleatum increase from rectum to cecum and accumulate gradually on normal colonic tissue in the adenoma-carcinoma sequence [53].

A layer of mucin containing bacteria on the luminal surface of the colonic epithelium is defined as bacterial biofilm [54]. This biofilm has been found to be invasive in approximately 90% of patients with colon cancer on the right side, while this has only been seen in about 10% of patients with cancer on the left side and subsequently, correlation between carcinogenesis and biofilms has been found in right colon cancer but not in left-sided cancer [55]. Epithelial E-cadherin has been found to be significantly decreased, whereas interleukin-6 is found increased and Stat-3 is activated when a biofilm is present, resulting in increased proliferation [56]. Association between high levels of pro-proliferative polyamine metabolite N, N-diacetylspermine, and biofilm in the lumen of the large bowel has been found, suggesting a relation between bacterial biofilms and host cancer [57]. Therefore, the formation of colonic bacterial biofilms with synchronous procarcinogenic epithelial responses has been suspected in the process of carcinogenesis in right-sided colon cancer [47].

Differences in bile acid levels

Bile acids (Bas) are produced in the liver by hepatocytes and only approximately 5%-10% of Bas pass the terminal ileum without getting absorbed and are deconjugated by bacterial bile salt hydrolases in the colon to secondary Bas [58]. Most of these molecules are absorbed by colon cells and returned to the liver to be reused. Bile acids, as well as their metabolites, have been associated with the development of colon cancer through different mechanisms such as angiogenesis, enhancing cancer cell proliferation, inhibiting apoptosis and assisting invasion [59]. The levels of these substances in the colonic lumen vary and are regulated by the normal colonic bacterial flora. Primary bile acids in the right colon interact with biofilms and microbiomes and are converted to secondary bile acids by means of deconjugation [60]. Deoxycholic acid (DCA) is the most found secondary bile acid and Lithocholic acid (LCA) is the second most common secondary bile acid. These acids are reabsorbed by the intestinal epithelial and subsequently alter DNA causing permanent damage through reactive oxygen and nitrogen species [59,60]. Conjugated primary bile acids are more commonly found in the right colon versus the left colon, almost 10 times more on the right [55]. Aspirates from the cecum and rectal fecal samples have been compared and have shown high levels of enzymatic activity, converting primary bile acids to DCA, in the cecal samples [61]. These findings suggest a possible role of differential bile acid levels according to location in colon cancer development.

Bas, when found in high concentrations in the large bowel, may cause cell membrane destruction, via their detergent properties, resulting in damage to intestinal epithelium. This situation promotes repair mechanisms that involve inflammatory cells and the proliferation and accumulation of undifferentiated cells [26,59]. This is a precancerous state which leads to formal carcinogenesis and CRC development. Furthermore, BAs have an oncogenic effect by making cells resistant to apoptosis [60]. This is possible by the degradation of tumor suppressor p53 by BAs which is responsible for cell processing of DNA repair and initiates apoptosis if DNA repair is not possible [62].


Polyps are commonly found in the colon and are considered precursors of colonic adenocarcinomas. Tubular and tubulovillous polyps are seen both on the right as well as the left side of the colon but they may present high-grade dysplasia and evolve into cancer more often on the right side of the colon, especially when found in smaller sizes [27]. Sessile serrated adenomas are also predominantly found in the cecum, ascending and transverse colon [27,42]. Comparatively, sessile serrated adenomas, found in right-sided colon cancer, present CIMP high levels, MSI high levels, MLH1 methylation and BRAF mutation while this is not seen in conventional adenomas found on both right and left sided colon cancer, whereas the opposite is seen for CIN where this is present in conventional polyps and not in sessile serrated polyps [43].


Colorectal cancer is a heterogeneous disease and is treated today based on the presence of MSI or driver mutations such as KRAS, NRAS and BRAF. Recent trials showed progress in the development of personalised treatments which use alternative genes. These alternative genes are possibly responsible for progression of disease. Alternative receptors tyrosine kinases beyond EGFR and HER2 and additional fusions beyond ALK and NTRK should be examined before initiation of treatment and can further improve outcomes in mCRC. Studies have found the presence of certain mutations that may indicate contraindications for some treatments, such as ARHGEF33. This gene is similar to KRAS/NRAS activating mutations and has a negative impact in anti-EGFR treatment [63].

In addition, some targeted therapies that are already in use in other cancers with very good results, namely Sotorasib, harbouring the KRAS pG12C mutation in non-small-cell lung cancer, should be further investigated for potential use in CRC.

Presently several types of immunotherapies are applied in the treatment of CRC. These include monoclonal antibodies, ICB to reinvigorate T-cell immunity, CAR-T cell therapy, oncolytic viruses and cancer vaccines. Furthermore, the activation of the immune system with therapeutic DNA cancer vaccines is a very promising approach. Pre-clinical trials have shown that monotherapy with these vaccines have not changed the outcomes of cancer, but the combination with other personalized treatments based on the patient’s genetic profile and biomarkers should be used. This way, effective treatments can be ensured and side-effects can be minimised [64].


As seen in this narrative, colorectal cancer presents major differences according to location regarding molecular characteristics which in turn, affects its histopathology, prognosis, and response to treatment. Overall, colorectal cancer cannot be considered a single disease but should be treated as 2 different diseases in the same organ [9,12]. The underlying causes of the reported molecular differences between colorectal tumor locations may be multifactorial. Environmental, genetic and immunological factors all play roles in the development and overall survival of colorectal cancer patients [26,32,40,53]. The clinical significance of these findings requires replication and additional studies need to be undertaken in larger populations. Indeed, nowadays, in the era of personalised medicine, sidedness is a major factor in the treatment of colorectal cancer and the biology and genetic pathways of this disease need to be studied further to determine potential targets for individualised treatment [63]. Therefore, there is a need for further research and broader genomic profiling for a better understanding of tumour biology, hopefully leading to new discoveries in diagnostics and therapeutics.

Conflicts of interest: The authors declare no conflict of interest

Funding Declaration: The authors of the review have no funding to declare.

  1. Araujo CS, Venchiarutti Moniz CM, Bonadio RC, Watarai GY, Rojas J, Nogueira PVS, et al. Real-world data for high-risk stage ii colorectal cancer – The role of tumor side in the adjuvant setting. Clin Colorectal Cancer. 2021 Jun;20(2):e100-8.
  2. Bretthauer M, Løberg M, Wieszczy P, Kalager M, Emilsson L, Garborg K, et al. Effect of colonoscopy screening on risks of colorectal cancer and related death. N Engl J Med. 2022 Oct;387(17):1547-56.
  3. Dienstmann R, Salazar R, Tabernero J. Personalizing colon cancer adjuvant therapy: selecting optimal treatments for individual patients. J Clin Oncol. 2015 Jun;33(16):1787-96.
  4. Cappell MS. Pathophysiology, clinical presentation, and management of colon cancer. Gastroenterol Clin North Am. 2008 Mar;37(1):1-24, v.
  5. Giovannucci E. Modifiable risk factors for colon cancer. Gastroenterol Clin North Am. 2002 Dec;31(4):925-43.
  6. Valle L, Vilar E, Tavtigian SV, Stoffel EM. Genetic predisposition to colorectal cancer: Syndromes, genes, classification of genetic variants and implications for precision medicine. J Pathol. 2019 Apr;247(5):574-88.
  7. Irving MH, Catchpole B. ABC of colorectal diseases. Anatomy and physiology of the colon, rectum, and anus. Bmj. 1992 Apr;304(6834):1106-8.
  8. Lee YS. Carcinoma of the large bowel in Singapore–a pathological study. Ann Acad Med Singap. 1988 Jan;17(1):55-65.
  9. Gervaz P, Bucher P, Morel P. Two colons-two cancers: paradigm shift and clinical implications. J Surg Oncol. 2004 Dec;88(4):261-6.
  10. Missiaglia E, Jacobs B, D’Ario G, Di Narzo AF, Soneson C, Budinska E, et al. Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features. Ann Oncol. 2014 Oct;25(10):1995-2001.
  11. Salem ME, Weinberg BA, Xiu J, El-Deiry WS, Hwang JJ, Gatalica Z, et al. Comparative molecular analyses of left-sided colon, right-sided colon, and rectal cancers. Oncotarget. 2017 Oct;8(49):86356-68.
  12. Cannon E, Buechler S. Colon cancer tumor location defined by gene expression may disagree with anatomic tumor location. Clin Colorectal Cancer. 2019 Jun;18(2):149-58.
  13. Tariq K, Ghias K. Colorectal cancer carcinogenesis: A review of mechanisms. Cancer Biol Med. 2016 Mar;13(1):120-35.
  14. Bhattacharya I, Barman N, Maiti M, Sarkar R. Assessment of beta-catenin expression by immunohistochemistry in colorectal neoplasms and its role as an additional prognostic marker in colorectal adenocarcinoma. Med Pharm Rep. 2019 Jul;92(3):246-52.
  15. Zhu G, Pei L, Xia H, Tang Q, Bi F. Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer. Molecular Cancer. 2021 Nov;20(1):143.
  16. Laporte GA, Leguisamo NM, Kalil AN, Saffi J. Clinical importance of DNA repair in sporadic colorectal cancer. Crit Rev Oncol Hematol. 2018 Jun;126:168-85.
  17. Jin Z, Sinicrope FA. Mismatch Repair-Deficient Colorectal Cancer: Building on Checkpoint Blockade. J Clin Oncol. 2022 Aug;40(24):2735-50.
  18. Okugawa Y, Grady WM, Goel A. Epigenetic alterations in colorectal cancer: Emerging biomarkers. Gastroenterology. 2015 Oct;149(5):1204-25.e12.
  19. De Palma FDE, D’Argenio V, Pol J, Kroemer G, Maiuri MC, Salvatore F. The molecular hallmarks of the serrated pathway in colorectal cancer. Cancers (Basel). 2019 Jul;11(7):1017.
  20. Mármol I, Sánchez-de-Diego C, Pradilla Dieste A, Cerrada E, Rodriguez Yoldi MJ. Colorectal carcinoma: A general overview and future perspectives in colorectal cancer. Int J Mol Sci. 2017 Jan;18(1):197.
  21. Pino MS, Chung DC. The chromosomal instability pathway in colon cancer. Gastroenterology. 2010 Jun;138(6):2059-72.
  22. Gymrek M. A genomic view of short tandem repeats. Curr Opin Genet Dev. 2017 Jun;44:9-16.
  23. Kim D, Fishel R, Lee JB. Coordinating Multi-Protein Mismatch Repair by Managing Diffusion Mechanics on the DNA. J Mol Biol. 2018 Oct;430(22):4469-80.
  24. Cohen R, Taieb J, Fiskum J, Yothers G, Goldberg R, Yoshino T, et al. Microsatellite instability in patients with stage iii colon cancer receiving fluoropyrimidine with or without oxaliplatin: An ACCENT pooled analysis of 12 adjuvant trials. J Clin Oncol. 2021 Feb;39(6):642-51.
  25. Kim ST, Lee J, Park SH, Park JO, Lim HY, Kang WK, et al. Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy. Cancer Chemother Pharmacol. 2010 Sep;66(4):659-67.
  26. Hirabayashi S, Hayashi M, Nakayama G, Mii S, Hattori N, Tanabe H, et al. The Significance of molecular biomarkers on clinical survival outcome differs depending on colon cancer sidedness. Anticancer Res. 2020 Jan;40(1):201-11.
  27. Baran B, Mert Ozupek N, Yerli Tetik N, Acar E, Bekcioglu O, Baskin Y. Difference between left-sided and right-sided colorectal cancer: A focused review of literature. Gastroenterology Res. 2018 Aug;11(4):264-73.
  28. Guinney J, Dienstmann R, Wang X, de Reyniès A, Schlicker A, Soneson C, et al. The consensus molecular subtypes of colorectal cancer. Nat Med. 2015 Nov;21(11):1350-6.
  29. Loree JM, Pereira AAL, Lam M, Willauer AN, Raghav K, Dasari A, et al. Classifying colorectal cancer by tumor location rather than sidedness highlights a continuum in mutation profiles and consensus molecular subtypes. Clin Cancer Res. 2018 Mar;24(5):1062-72.
  30. Peters NA, Constantinides A, Ubink I, van Kuik J, Bloemendal HJ, van Dodewaard JM, et al. Consensus molecular subtype 4 (CMS4)-targeted therapy in primary colon cancer: A proof-of-concept study. Front Oncol [Internet]. 2022 Sep;12:969855. Available from:
  31. Fiala O, Ostasov P, Hosek P, Sorejs O, Liska V, Buchler T, et al. The predictive role of primary tumour sidedness in metastatic colorectal cancer treated with targeted agents. Anticancer Res. 2019 Oct;39(10):5645-52.
  32. Noepel-Duennebacke S, Arnold D, Hertel J, Tannapfel A, Hinke A, Hegewisch-Becker S, et al. Impact of the localization of the primary tumor and RAS/BRAF mutational status on maintenance strategies after First-line Oxaliplatin, Fluoropyrimidine, and Bevacizumab in metastatic colorectal cancer: Results From the AIO 0207 Trial. Clin Colorectal Cancer. 2018 Dec;17(4):e733-9.
  33. Charlton ME, Kahl AR, Greenbaum AA, Karlitz JJ, Lin C, Lynch CF, et al. KRAS Testing, Tumor location, and survival in patients with stage iv colorectal cancer: SEER 2010-2013. J Natl Compr Canc Netw. 2017 Dec;15(12):1484-93.
  34. Syed Sameer A, Abdullah S, Banday M, Syeed N, Siddiqi M. Colorectal cancer, TGF-β signaling and SMADs. International Journal of Genetics and Molecular Biology. 2010 Jun;2(6):101-11.
  35. Sanz-Garcia E, Argiles G, Elez E, Tabernero J. BRAF mutant colorectal cancer: Prognosis, treatment, and new perspectives. Annals of Oncology. 2017 Nov;28(11):2648-57.
  36. Advani SM, Advani P, DeSantis SM, Brown D, VonVille HM, Lam M, et al. Clinical, pathological, and molecular characteristics of CpG island methylator phenotype in colorectal cancer: A systematic review and meta-analysis. Transl Oncol. 2018 Oct;11(5):1188-201.
  37. Salem ME, Battaglin F, Goldberg RM, Puccini A, Shields AF, Arguello D, et al. Molecular analyses of left- and right-sided tumors in adolescents and young adults with colorectal cancer. Oncologist. 2020 May;25(5):404-13.
  38. Hu H, Zhang Q, Huang R, Gao Z, Yuan Z, Tang Q, et al. Genomic Analysis Reveals Heterogeneity Between Lesions in Synchronous Primary Right-Sided and Left-Sided Colon Cancer. Frontiers in Molecular Biosciences [Internet]. 2021 Aug;8:689466. Available from:
  39. Chika N, Eguchi H, Kumamoto K, Suzuki O, Ishibashi K, Tachikawa T, et al. Prevalence of lynch syndrome and lynch-like syndrome among patients with colorectal cancer in a Japanese hospital-based population. Jpn J Clin Oncol. 2017 Feb;47(2):108-17.
  40. Takasu C, Nishi M, Yoshikawa K, Tokunaga T, Kashihara H, Yoshimoto T, et al. Impact of sidedness of colorectal cancer on tumor immunity. PLoS One [Internet]. 2020;15(10):e0240408. Available from:
  41. Liu LU, Holt PR, Krivosheyev V, Moss SF. Human right and left colon differ in epithelial cell apoptosis and in expression of Bak, a pro-apoptotic Bcl-2 homologue. Gut. 1999 Jul;45(1):45-50.
  42. Yang JF, Tang S-J, Lash RH, Wu R, Yang Q. Anatomic distribution of sessile serrated adenoma/polyp with and without cytologic dysplasia. Arch Pathol Lab Med. 2015 Mar;139(3):388-93.
  43. Nojadeh JN, Behrouz Sharif S, Sakhinia E. Microsatellite instability in colorectal cancer. Excli j. 2018 Jan;17:159-68.
  44. Song M, Chan AT. Environmental Factors, Gut Microbiota, and Colorectal Cancer Prevention. Clin Gastroenterol Hepatol. 2019 Jan;17(2):275-89.
  45. Wong SH, Yu J. Gut microbiota in colorectal cancer: mechanisms of action and clinical applications. Nat Rev Gastroenterol Hepatol. 2019 Nov;16(11):690-704.
  46. Cheng Y, Ling Z, Li L. The Intestinal Microbiota and Colorectal Cancer. Front Immunol [Internet]. 2020 Nov;11:615056. Available from:
  47. Hecht AL, Casterline BW, Choi VM, Bubeck Wardenburg J. A two-component system regulates bacteroides fragilis toxin to maintain intestinal homeostasis and prevent lethal disease. Cell Host Microbe. 2017 Oct;22(4):443-8.e5.
  48. Suresh A, Ranjan A, Jadhav S, Hussain A, Shaik S, Alam M, et al. Molecular Genetic and Functional Analysis of pks-Harboring, Extra-Intestinal Pathogenic Escherichia coli From India. Front Microbiol [Internet]. 2018 Nov;9:2631. Available from:
  49. Shine EE, Xue M, Patel JR, Healy AR, Surovtseva YV, Herzon SB, et al. Model colibactins exhibit human cell genotoxicity in the absence of host bacteria. ACS Chem Biol. 2018 Dec;13(12):3286-93.
  50. Kohoutova D, Smajs D, Moravkova P, Cyrany J, Moravkova M, Forstlova M, et al. Escherichia coli strains of phylogenetic group B2 and D and bacteriocin production are associated with advanced colorectal neoplasia. BMC Infect Dis. 2014 Dec;14:733.
  51. Hashemi Goradel N, Heidarzadeh S, Jahangiri S, Farhood B, Mortezaee K, Khanlarkhani N, et al. Fusobacterium nucleatum and colorectal cancer: A mechanistic overview. J Cell Physiol. 2019 Mar;234(3):2337-44.
  52. Brennan CA, Garrett WS. Fusobacterium nucleatum – symbiont, opportunist and oncobacterium. Nat Rev Microbiol. 2019 Mar;17(3):156-66.
  53. Kwak HD, Ju JK. Immunological differences between right-sided and left-sided colorectal cancers: A comparison of embryologic midgut and hindgut. Ann Coloproctol [Internet]. 2019 Dec;35(6):342-6. Available from:
  54. Mirzaei R, Mirzaei H, Alikhani MY, Sholeh M, Arabestani MR, Saidijam M, et al. Bacterial biofilm in colorectal cancer: What is the real mechanism of action? Microb Pathog [Internet]. 2020 Feb;142:104052. Available from:
  55. Yang SY, Cho MS, Kim NK. Difference between right-sided and left-sided colorectal cancers: from embryology to molecular subtype. Expert Rev Anticancer Ther. 2018 Apr;18(4):351-8.
  56. Cheng WT, Kantilal HK, Davamani F. The Mechanism of bacteroides fragilis toxin contributes to colon cancer formation. Malays J Med Sci. 2020 Jul;27(4):9-21.
  57. Johnson CH, Dejea CM, Edler D, Hoang LT, Santidrian AF, Felding BH, et al. Metabolism links bacterial biofilms and colon carcinogenesis. Cell Metab. 2015 Jun;21(6):891-7.
  58. Martinez-Augustin O, Sanchez de Medina F. Intestinal bile acid physiology and pathophysiology. World J Gastroenterol. 2008 Oct;14(37):5630-40.
  59. Nguyen TT, Ung TT, Kim NH, Jung YD. Role of bile acids in colon carcinogenesis. World J Clin Cases. 2018 Nov;6(13):577-88.
  60. Ajouz H, Mukherji D, Shamseddine A. Secondary bile acids: An underrecognized cause of colon cancer. World J Surg Oncol. 2014 May;12(1):164.
  61. Kulanthaivel S, Boccuto L, Zanza C, Longhitano Y, Balasundaram K, Méndez-Sánchez N, et al. Biliary acids as promoters of colon carcinogenesis: A narrative review. Dig Med Res. 2021 Jun;4(33).
  62. Aubrey BJ, Kelly GL, Janic A, Herold MJ, Strasser A. How does p53 induce apoptosis and how does this relate to p53-mediated tumour suppression? Cell Death Differ. 2018 Jan;25(1):104-13.
  63. Tsimberidou AM, Fountzilas E, Nikanjam M, Kurzrock R. Review of precision cancer medicine: Evolution of the treatment paradigm. Cancer Treat Rev. 2020 Jun;86:102019.
  64. Gmeiner WH. Recent advances in our knowledge of mcrc tumor biology and genetics: A focus on targeted therapy development. Onco Targets Ther [Internet]. 2021 Mar;14:2121-30. Available from:
  65. Hasbullah HH, Musa M. Gene therapy targeting p53 and kras for colorectal cancer treatment: A myth or the way forward? Int J Mol Sci. 2021 Nov 3;22(21):11941. doi: 10.3390/ijms222111941. PMID: 34769370; PMCID: PMC8584926.